Miyazaki, Dai
Eguchi, Hiroshi
Kuwahara, Tomomi
Nakayama-Imaohji, Haruyuki
Inaba, Masamaru
Itoi, Motozumi
Ueda, Kiichi
Ohashi, Yuichi
Sado, Kazushige
Mizutani, Satoshi
Miyamoto, Hitoshi
Sasaki, Shin-ichi
Shimizu, Yumiko
Inoue, Yoshitsugu
Article History
Received: 6 March 2020
Accepted: 8 July 2020
First Online: 28 July 2020
Competing interests
: Tomomi Kuwahara, Haruyuki Nakayama-Imaohji, Masamaru Inaba, Motozumi Itoi, Kiichi Ueda, Yuichi Ohashi, Kazushige Sado, Satoshi Mizutani, Hitoshi Miyamoto, Shin-ichi Sasaki, and Yumiko Shimizu declare no competing interests.
: Dai Miyazaki reports lecture fee from Santen Pharmaceutical, Senju Pharmaceutical, Alcon, outside the submitted work. Hiroshi Eguchi reports lecture fees from Santen Pharmaceutical, Senju Pharmaceutical, Novartis Pharma, Kowa, Nitten Pharmaceutical, Nitto Medic, and Seed outside the submitted work. Hiroshi Eguchi has received grant funding from Pfizer Japan Inc. outside the submitted work. Hiroshi Eguchi has a consultant contract with Otsuka Pharmaceutical outside the submitted work. Yoshitsugu Inoue reports grants and lecture fee from Senju Pharmaceutical Co, Ltd., grants from Santen Pharmaceutical Co, Ltd., grants from Alcon Japan, Ltd., outside the submitted work.